Patented inhibitors (2002 – 2005) of the transcription factor NF-κB

Abstract

Nuclear factor-κB (NF-κB) is a central transcriptional factor and a pleiotropic regulator of many genes involved in immunological responses. Dysregulation of NF-κB can lead to a wide variety of diseases, including those related to inflammation and cancer. Therefore, NF-κB and the signalling pathways that regulate its activity have become a focal point for intense drug discovery and development by a number of drug companies and academic groups. Small-molecule inhibitors of regulatory enzymes or of NF-κB itself, gene therapy, decoy oligonucleotides or various biologicals have been reported and patented as potential candidates for drug development. This article reviews patents claiming NF-κB inhibitors during the period 2002 – 2005. Some of these inhibitors may be developed to therapeutics and used for the treatment of inflammatory diseases and tumour chemoresistance.

Keywords::

• chemoresistance
• inflammatory diseases
• NF-κB

Acknowledgement

The author apologises for failing to cite many relevant primary papers because of space constraints. The author gratefully acknowlegdes financial support by the BMBF (Hepatosys project).